Loading clinical trials...
Loading clinical trials...
Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis
Conditions
Interventions
Onabotulinum Toxin Type A - Phase 1b
Onabotulinum Toxin Type A - Phase 2
Locations
2
United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
UPMC Department of Dermatology
Pittsburgh, Pennsylvania, United States
Start Date
July 17, 2025
Primary Completion Date
December 15, 2026
Completion Date
January 1, 2027
Last Updated
February 3, 2026
NCT07298395
NCT07316465
NCT07235384
NCT07259343
NCT07204561
NCT07021495
Lead Sponsor
Daniel Kaplan
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions